Walid Shaib, MD
Hematology & Oncology · New Haven, CTNPI 1831372481
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $135,758 of the $217,067 with a category attached, or 62.5%. 60 manufacturers reported payments, led by Exelixis Inc. at 30.4% of the total. 2025 is the largest year on record at $130,346, more than ten times the $6,339 reported in 2019. Among hematology & oncology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 575 payments — averaging $377.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$66K
- Jazz Pharmaceuticals Inc.$37K
- Seagen Inc.$32K
- AstraZeneca$26K
- Pfizer$15K
- E.r. Squibb & Sons, L.L.C.$8K
- plus $33K from 54 others
Across 54 payments — averaging $31,990 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$539K
- Novartis$489K
- Lilly USA, LLC$370K
- E.r. Squibb & Sons, L.L.C.$87K
- AstraZeneca$81K
- Merck$61K
- plus $100K from 6 others
What the payments were for
- Consulting fees$47,97222%
- Speaking & faculty fees$135,75863%
- Travel & lodging$21,08510%
- Food & beverage$11,3985%
- Education$8550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$217,067 in reported general payments places this provider in the 95th percentile of 163 hematology & oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 20 | $355,708 |
| BrukinsaZanubrutinib | 23 | $348,624 |
| IbrancePalbociclib | 22 | $343,395 |
| Lenalidomide | 22 | $327,452 |
| RevlimidLenalidomide | 17 | $281,599 |
| CalquenceAcalabrutinib Maleate | 17 | $198,617 |
| EliquisApixaban | 111 | $74,687 |
| XareltoRivaroxaban | 44 | $44,725 |
| Abiraterone Acetate | 19 | $25,620 |
| Ondansetron Hcl | 133 | $5,919 |
| Imatinib Mesylate | 16 | $3,504 |
| Exemestane | 11 | $1,867 |
| Letrozole | 80 | $1,396 |
| Prochlorperazine Maleate | 100 | $1,110 |
| SpsSodium Polystyrene Sulfon/Sorb | 30 | $1,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $14,980 | $418,083133 claims |
| Incyte CorporationJakafi | $5,239 | $355,70820 claims |
| Beigene USA, Inc.Brukinsa | $37 | $348,62423 claims |
| Bristol Myers SquibbRevlimid | $411 | $281,59917 claims |
| AstraZenecaCalquence | $25,813 | $198,61717 claims |
| Johnson & JohnsonXarelto | $724 | $44,72544 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $2,310 | $25,62019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in New Haven
- Amer ZeidanNew Haven$807K
- Scott HuntingtonNew Haven$163K
- Nataliya UbohaNew Haven$124K
- Michael CecchiniNew Haven$103K
- Iris IsufiNew Haven$73K
- Maximilian StahlNew Haven$34K
- Shalin KothariNew Haven$24K
- John RobertsNew Haven$17K
- Biree AndemariamFarmington$646K
- Paul WeinsteinStamford$288K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.